Phospholipase C beta (PLC-beta)

Phospholipase C beta (PLCβ) is a family of four enzyme isoforms (PLCβ1–4) that serve as critical transducers in the phosphoinositide signaling pathway. These enzymes are primarily activated by G protein-coupled receptors (GPCRs) through the Gαq subfamily of G proteins or Gβγ subunits (UniProt: P23443, Q01970). Once activated, PLCβ catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce two potent second messengers: inositol 1,4,5-trisphosphate (IP3), which triggers calcium release from the endoplasmic reticulum, and diacylglycerol (DAG), which activates protein kinase C (PKC). This signaling cascade is vital for various physiological processes, including muscle contraction, neurotransmission, and cell proliferation (PubMed: 28834749). Dysregulation or genetic mutations in PLCβ isoforms are linked to significant pathologies, such as infantile-onset epilepsy, schizophrenia, and various forms of cancer (PMC: 6429321). While research compounds like U-73122 are widely used to study PLCβ inhibition in laboratory settings, the development of clinically approved isoform-specific drugs remains a high priority for treating neurological and inflammatory disorders.

Other names

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase betaPhosphoinositide phospholipase C-betaPLC-BPLC-beta familyG-protein-regulated phospholipase C

Drugs targeting Phospholipase C beta typically act as small-molecule inhibitors that block the catalytic site or interfere with the interaction between the enzyme and its G-protein activators (Gαq or Gβγ), thereby preventing the hydrolysis of PIP2 into IP3 and DAG and dampening downstream calcium and PKC signaling (PubMed: 28834749, PMC: 6429321).